These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
282 related articles for article (PubMed ID: 8737030)
1. Daytime glibenclamide and bedtime NPH insulin compared to intensive insulin treatment in secondary sulphonylurea failure: a 1-year follow-up. Clauson P; Karlander S; Steen L; Efendic S Diabet Med; 1996 May; 13(5):471-7. PubMed ID: 8737030 [TBL] [Abstract][Full Text] [Related]
2. Comparison of bedtime NPH or preprandial regular insulin combined with glibenclamide in secondary sulfonylurea failure. Landstedt-Hallin L; Adamson U; Arner P; Bolinder J; Lins PE Diabetes Care; 1995 Aug; 18(8):1183-6. PubMed ID: 7587856 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of combined treatments in NIDDM patients with secondary failure to sulphonylureas. Is it predictable? Trischitta V; Italia S; Raimondo M; Guardabasso V; Licciardello C; Runello F; Mazzarino S; Sangiorgi L; Anello M; Vigneri R J Endocrinol Invest; 1998 Dec; 21(11):744-7. PubMed ID: 9972673 [TBL] [Abstract][Full Text] [Related]
4. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Yki-Järvinen H; Dressler A; Ziemen M; Diabetes Care; 2000 Aug; 23(8):1130-6. PubMed ID: 10937510 [TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of normalizing fasting glucose with bedtime NPH insulin alone in NIDDM. Cusi K; Cunningham GR; Comstock JP Diabetes Care; 1995 Jun; 18(6):843-51. PubMed ID: 7555511 [TBL] [Abstract][Full Text] [Related]
6. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients. Chow CC; Tsang LW; Sorensen JP; Cockram CS Diabetes Care; 1995 Mar; 18(3):307-14. PubMed ID: 7555472 [TBL] [Abstract][Full Text] [Related]
7. Comparison of combined therapies in treatment of secondary failure to glyburide. Trischitta V; Italia S; Mazzarino S; Buscema M; Rabuazzo AM; Sangiorgio L; Squatrito S; Vigneri R Diabetes Care; 1992 Apr; 15(4):539-42. PubMed ID: 1499473 [TBL] [Abstract][Full Text] [Related]
8. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group. Bastyr EJ; Stuart CA; Brodows RG; Schwartz S; Graf CJ; Zagar A; Robertson KE Diabetes Care; 2000 Sep; 23(9):1236-41. PubMed ID: 10977012 [TBL] [Abstract][Full Text] [Related]
9. Acarbose vs. bedtime NPH insulin in the treatment of secondary failures to sulphonylurea-metformin therapy in type 2 diabetes mellitus. López-Alvarenga JC; Aguilar-Salinas CA; Velasco-Perez ML; Arita-Melzer O; Guillen LE; Wong B; Brito G; Mercado V; Gómez-Pérez FJ; Rull-Rodrigo JA Diabetes Obes Metab; 1999 Jan; 1(1):29-35. PubMed ID: 11221809 [TBL] [Abstract][Full Text] [Related]
10. Comparison of different insulin regimens in elderly patients with NIDDM. Wolffenbuttel BH; Sels JP; Rondas-Colbers GJ; Menheere PP; Nieuwenhuijzen Kruseman AC Diabetes Care; 1996 Dec; 19(12):1326-32. PubMed ID: 8941458 [TBL] [Abstract][Full Text] [Related]
11. Combination-therapy with bedtime nph insulin and sulphonylureas gives similar glycaemic control but lower weight gain than insulin twice daily in patients with type 2 diabetes. Olsson PO; Lindström T Diabetes Metab; 2002 Sep; 28(4 Pt 1):272-7. PubMed ID: 12442064 [TBL] [Abstract][Full Text] [Related]
12. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes. Abraira C; Colwell JA; Nuttall FQ; Sawin CT; Nagel NJ; Comstock JP; Emanuele NV; Levin SR; Henderson W; Lee HS Diabetes Care; 1995 Aug; 18(8):1113-23. PubMed ID: 7587846 [TBL] [Abstract][Full Text] [Related]
13. Comparison of bedtime NPH insulin or metformin combined with glibenclamide in secondary sulphonylurea failure in obese type II (NIDDM) patients. Niazi R; Muzaffar Z J Pak Med Assoc; 1998 Nov; 48(11):336-8. PubMed ID: 10323055 [TBL] [Abstract][Full Text] [Related]
14. Comparison of lunch and bedtime NPH insulin plus mealtime insulin Lispro therapy with premeal regular insulin plus bedtime NPH insulin therapy in type 2 diabetes. Sargin H; Sargin M; Altuntaş Y; Sengül AM; Orbay E; Seber S; Uçak S; Yayla A Diabetes Res Clin Pract; 2003 Nov; 62(2):79-86. PubMed ID: 14581144 [TBL] [Abstract][Full Text] [Related]
15. Insulin in type 2 diabetes: a useful alternative despite limited assessment based on surrogate endpoints. Prescrire Int; 2005 Oct; 14(79):187-93. PubMed ID: 16285076 [TBL] [Abstract][Full Text] [Related]
16. Comparison of additional metformin or NPH insulin to mealtime insulin lispro therapy with mealtime human insulin therapy in secondary OAD failure. Altuntas Y; Ozen B; Ozturk B; Sengul A; Ucak S; Ersoy O; Karul S Diabetes Obes Metab; 2003 Nov; 5(6):371-8. PubMed ID: 14617222 [TBL] [Abstract][Full Text] [Related]
17. Bed time NPH-insulin plus combined sulfonylurea-biguanide oral therapy for treating refractory non insulin dependent diabetic patients. di Cianni G; Benzi L; Ciccarone AM; Cecchetti P; Navalesi R Diabete Metab; 1992; 18(6):468-9. PubMed ID: 1297606 [No Abstract] [Full Text] [Related]
18. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Yki-Järvinen H; Ryysy L; Nikkilä K; Tulokas T; Vanamo R; Heikkilä M Ann Intern Med; 1999 Mar; 130(5):389-96. PubMed ID: 10068412 [TBL] [Abstract][Full Text] [Related]
19. Metformin's effects on glucose and lipid metabolism in patients with secondary failure to sulfonylureas. Fanghänel G; Sánchez-Reyes L; Trujillo C; Sotres D; Espinosa-Campos J Diabetes Care; 1996 Nov; 19(11):1185-9. PubMed ID: 8908377 [TBL] [Abstract][Full Text] [Related]
20. Indirect comparison of lixisenatide versus neutral protamine Hagedorn insulin as add-on to metformin and sulphonylurea in patients with type 2 diabetes mellitus. Fournier M; Germe M; Theobald K; Scholz GH; Lehmacher W Ger Med Sci; 2014; 12():Doc14. PubMed ID: 25332702 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]